{'52WeekChange': 0.32196963,
 'SandP52WeekChange': 0.0644362,
 'address1': '131 Hartwell Avenue',
 'address2': 'Suite 320',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.05,
 'askSize': 1400,
 'averageDailyVolume10Day': 1430125,
 'averageVolume': 1365184,
 'averageVolume10days': 1430125,
 'beta': 2.108683,
 'beta3Year': None,
 'bid': 6.7,
 'bidSize': 1800,
 'bookValue': 1.473,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lexington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.15,
 'dayLow': 6.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.343,
 'enterpriseToRevenue': None,
 'enterpriseValue': 184407600,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '339 674 6495',
 'fiftyDayAverage': 4.9754286,
 'fiftyTwoWeekHigh': 8.05,
 'fiftyTwoWeekLow': 1.48,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25877781,
 'forwardEps': -1.58,
 'forwardPE': -4.4177213,
 'fromCurrency': None,
 'fullTimeEmployees': 15,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0401,
 'heldPercentInstitutions': 0.65874,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aldeyra.com',
 'longBusinessSummary': 'Aldeyra Therapeutics, Inc., a biotechnology company, '
                        'develops and commercializes medicines for '
                        'immune-mediated ocular and systemic diseases. The '
                        "company's lead product candidate is reproxalap, an "
                        'ophthalmic solution, which is in Phase III clinical '
                        'trial for the treatment of dry eye diseases and '
                        'allergic conjunctivitis. It also develops ADX-2191, a '
                        'dihydrofolate reductase inhibitor which is in phase 3 '
                        'for the prevention of proliferative '
                        'vitreoretinopathy, a sight-threatening retinal '
                        "disease. The company's portfolio also consists of "
                        'ADX-1612, a small molecule heat shock protein 90 '
                        '(Hsp90) inhibitor for the treatment of '
                        'lymphoproliferative diseases; and reactive aldehyde '
                        'species that are pro-inflammatory (RASP) scavengers, '
                        'such as ADX-629 for treating autoimmune diseases, as '
                        'well as ADX-103 for the treatment of retinal '
                        'diseases. The company was formerly known as Aldexa '
                        'Therapeutics, Inc. and changed its name to Aldeyra '
                        'Therapeutics, Inc. in March 2014. Aldeyra '
                        'Therapeutics, Inc. was founded in 2004 and is '
                        'headquartered in Lexington, Massachusetts.',
 'longName': 'Aldeyra Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 239913072,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_47399863',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -55070964,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.49,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.06,
 'phone': '781 761 4904',
 'previousClose': 6.33,
 'priceHint': 2,
 'priceToBook': 4.7386284,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.15,
 'regularMarketDayLow': 6.3,
 'regularMarketOpen': 6.49,
 'regularMarketPreviousClose': 6.33,
 'regularMarketPrice': 6.49,
 'regularMarketVolume': 2061860,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34371500,
 'sharesPercentSharesOut': 0.0211,
 'sharesShort': 629119,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 732207,
 'shortName': 'Aldeyra Therapeutics, Inc.',
 'shortPercentOfFloat': 0.025999999,
 'shortRatio': 0.54,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ALDX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.992,
 'twoHundredDayAverage': 4.2020864,
 'volume': 2061860,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aldeyra.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02421'}